RxDoctor Payments DataLook up a doctor →

Adnan Alghadban, MD

Neurology · Bridgeport, WVNPI 1043323199

Payments from drug & device makers

$26,911in general payments, 2019–2025

Across 1,413 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AstraZeneca$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • AbbVie$2K
  • MDD US Operations, LLC$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$26,30198%
  • Education$5902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.196$2,930
AstraZeneca(2 entities)85$2,137
Teva Pharmaceuticals USA, Inc.121$1,813
Jazz Pharmaceuticals Inc.110$1,769
AbbVie(2 entities)93$1,607
MDD US Operations, LLC23$1,259
Biogen53$1,091
Argenx US, Inc.45$1,073
Novartis58$993
Lundbeck LLC41$886
SK Life Science, Inc.30$733
Lilly USA, LLC38$678
Neurocrine Biosciences, Inc.33$660
Pfizer36$610
Sunovion Pharmaceuticals Inc.34$585
Acadia Pharmaceuticals Inc24$550
Genentech USA, Inc.29$537
Adamas Pharmaceuticals, Inc.34$531
Axsome Therapeutics, Inc.21$531
Bristol Myers Squibb27$487
Sanofi20$487
Greenwich Biosciences, Inc.20$443
Amneal Pharmaceuticals LLC20$400
Harmony Biosciences LLC29$388
Neurelis, Inc.15$357
Amgen15$351
Eisai Inc.12$322
Kyowa Kirin, Inc.15$322
Tanabe Pharma America, Inc.12$280
Supernus Pharmaceuticals, Inc.34$279
Abbott15$247
EMD Serono, Inc.11$225
Avanir Pharmaceuticals, Inc.7$171
Biohaven Pharmaceutical Holding Company Ltd.6$139
Scilex Pharmaceuticals Inc.5$104
Merz Pharmaceuticals, LLC4$91
Biohaven Pharmaceuticals, Inc.3$68
Takeda Pharmaceuticals U.S.A., Inc.2$62
Impel Pharmaceuticals Inc.3$59
Livanova USA, Inc.3$58
Upsher-smith Laboratories LLC3$48
Xeris Pharmaceuticals, Inc.2$48
Mallinckrodt Hospital Products Inc.2$47
Bayer3$44
Arbor Pharmaceuticals, Inc.2$41
Vanda Pharmaceuticals Inc.2$41
Portola Pharmaceuticals, LLC2$38
Currax Pharmaceuticals LLC2$33
Akcea Therapeutics, Inc.1$28
Medtronic1$26
Avadel CNS Pharmaceuticals, LLC1$26
Exact Sciences1$23
GRT US Holding, Inc.2$23
Grifols USA, LLC1$22
Inspire Medical Systems, Inc.1$22
Aquestive Therapeutics, Inc.1$21
Acorda Therapeutics, Inc1$20
Johnson & Johnson1$18
E.r. Squibb & Sons, L.L.C.1$17
Strongbridge US Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,911 in reported general payments places this provider in the 80th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$670,442
Medicare patients
719
Services billed
10,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab24$616,237
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$289,004
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$262,228
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5013$218,020
TecfideraDimethyl Fumarate12$111,072
AubagioTeriflunomide12$110,066
BriviactBrivaracetam82$109,742
AptiomEslicarbazepine Acetate68$99,300
XcopriCenobamate43$58,658
Emgality PenGalcanezumab-Gnlm40$35,386
NeuproRotigotine17$31,436
Lacosamide163$19,851
QuliptaAtogepant15$17,162
Nurtec OdtRimegepant Sulfate14$15,854
BotoxOnabotulinumtoxina13$9,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$2,137$616,23724 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$62$289,00424 claims
Grifols USA, LLCGamunex-C$22$262,22826 claims
UCB, Inc.Briviact, Neupro$2,930$141,17899 claims
BiogenTecfidera$1,091$111,07212 claims
SanofiAubagio$487$110,06612 claims
Sunovion Pharmaceuticals Inc.Aptiom$585$99,30068 claims
SK Life Science, Inc.Xcopri$733$58,65843 claims
AbbVieQulipta, Botox$1,607$26,63128 claims
PfizerNurtec Odt$610$15,85414 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$400$7,393127 claims
Upsher-smith Laboratories LLCTopiramate$48$2,523254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 neurology providers in West Virginia.

Other neurology in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →